Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Tesamorelin and ipamorelin are two injectable peptides that signal your pituitary gland to release more of your body's own growth hormone. Tesamorelin is a growth hormone releasing hormone (GHRH) analog and is FDA-approved as Egrifta for HIV-associated lipodystrophy [1]. Ipamorelin is a selective growth hormone releasing peptide (GHRP) that is not FDA-approved and is available in the U.S. only through licensed compounding pharmacies [2]. Clinicians often pair them off-label in longevity and metabolic care because the two act on different receptors and amplify each other's effect.
What are tesamorelin and ipamorelin?
Tesamorelin: a GHRH analog
Tesamorelin is a synthetic version of growth hormone releasing hormone (GHRH), the natural signal your hypothalamus sends to the pituitary gland. When tesamorelin binds the GHRH receptor on the pituitary, the gland releases a pulse of growth hormone (GH). It is sold under the brand name Egrifta and was FDA-approved in 2010 to reduce excess belly fat in adults with HIV-associated lipodystrophy [1].
Ipamorelin: a selective growth hormone secretagogue
Ipamorelin is a growth hormone releasing peptide (GHRP). It mimics ghrelin and binds the ghrelin receptor (GHS-R) on the pituitary, which triggers a separate GH pulse. Unlike older GHRPs, ipamorelin is highly selective — it raises GH without meaningfully raising cortisol, prolactin, or hunger signals [4]. Ipamorelin is not FDA-approved as a finished drug; in the U.S. it is dispensed only through licensed 503A compounding pharmacies with a prescription.
How do tesamorelin and ipamorelin work together?
The GHRH + GHRP synergy
Tesamorelin and ipamorelin act on two different receptors that both control GH release. Stimulating both at once produces a larger GH pulse than either alone — a synergy first described with GHRH plus GHRP-6 and confirmed with newer GHRPs [5]. The combination is often grouped with other peptide pairs like CJC-1295 plus ipamorelin, which use the same logic with a longer-acting GHRH analog.
Effect on natural growth hormone pulses
Healthy adults release GH in pulses, mostly at night. Tesamorelin and ipamorelin are designed to preserve that pulsed pattern rather than flood the body with steady hormone, which is part of why they are studied as a more physiologic alternative to recombinant human GH [5]. The downstream effect is a rise in insulin-like growth factor 1 (IGF-1), the liver-produced hormone that mediates most of GH's tissue effects.
What is tesamorelin FDA-approved for?
Egrifta and HIV-associated lipodystrophy
Tesamorelin's only FDA approval is for reducing excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy [1]. In the pivotal Phase 3 trial, patients lost roughly 15% of visceral fat over 26 weeks, with reductions in triglycerides [3].
Off-label uses in longevity and body composition
Outside of HIV-associated lipodystrophy, tesamorelin is used off-label for non-alcoholic fatty liver disease, age-related body composition changes, and general longevity protocols. Small studies have shown tesamorelin can reduce liver fat in people with HIV and NAFLD [6], but it is not approved for these uses and the long-term picture in healthy adults is still being studied.
Is ipamorelin FDA-approved?
Regulatory status and compounding considerations
Ipamorelin is not FDA-approved as a finished drug product [2]. In late 2023 the FDA placed ipamorelin on its list of bulk substances that cannot be used by 503B outsourcing facilities, citing safety and characterization concerns [7]. It can still be compounded in 503A pharmacies for an individual patient with a valid prescription. If you are considering ipamorelin, ask where the active ingredient is sourced and whether the pharmacy is state-licensed.
What are the potential benefits of combining tesamorelin and ipamorelin?
The benefits below come mainly from tesamorelin's HIV-lipodystrophy studies and from smaller trials of GHRH/GHRP combinations. They should be read as what these peptides have been investigated for, not guaranteed outcomes. Individual results vary.
Visceral fat reduction
The strongest evidence is for visceral (belly) fat. Tesamorelin reduced VAT by about 15% over 26 weeks in patients with HIV-associated lipodystrophy [3]. Some clinicians extend this rationale off-label to adults with central adiposity, though direct trial evidence in non-HIV populations is limited.
Lean muscle and recovery
By raising GH and IGF-1, the combination may support lean tissue maintenance and recovery from exercise [5]. It is not an anabolic steroid and is not approved as a performance-enhancing therapy.
Sleep and energy
Because most natural GH release happens during deep sleep, peptides that amplify the nighttime pulse are often reported to improve subjective sleep quality and daytime energy. Controlled data on these endpoints are limited, and reported benefits must be weighed against the side effects described below.
What are the side effects and risks?
Common side effects
Reported side effects of tesamorelin include injection-site redness or itching, joint aches, swelling in the hands or feet (fluid retention), muscle pain, and rash [1]. Ipamorelin is generally well-tolerated in short trials, with headache and flushing the most common complaints [4]. Both can raise IGF-1; if levels go too high, symptoms like carpal tunnel, joint pain, or insulin resistance can occur.
Who should avoid these peptides
Growth hormone-stimulating peptides are contraindicated or generally avoided in people with active cancer, during pregnancy or breastfeeding, in those with pituitary disorders or recent pituitary surgery, and in people with severe critical illness [1]. Anyone with diabetes, prediabetes, or untreated thyroid disease should be evaluated carefully because GH can affect insulin sensitivity.
Cancer and IGF-1 considerations
Because IGF-1 supports cell growth, raising it has theoretical cancer-promotion concerns. The Egrifta label carries a warning about use in patients with active malignancy [1]. Long-term safety data in healthy adults using GHRH/GHRP combinations off-label do not yet exist, which is why ongoing clinician monitoring of IGF-1 and routine cancer screening matter.
How is tesamorelin and ipamorelin typically dosed?
Common protocols
Tesamorelin is administered as a daily subcutaneous injection; the FDA-approved Egrifta dose for HIV-associated lipodystrophy is 2 mg once daily [1]. Ipamorelin, when compounded, is usually dosed in microgram amounts subcutaneously, once to three times daily, often at bedtime to align with the natural nighttime GH pulse. These are general ranges from the published literature, not personal recommendations.
Why dosing must be clinician-directed
The right dose depends on age, baseline IGF-1, body composition, goals, other medications, and screening labs. A clinician typically checks IGF-1 before starting and again after a few weeks, then adjusts. Self-dosing from research-only vials or unlicensed sources is unsafe and, in the U.S., illegal.
Tesamorelin vs ipamorelin vs other peptides
| Peptide | Class | FDA status | Typical role | Notable points |
|---|---|---|---|---|
| Tesamorelin (Egrifta) | GHRH analog | FDA-approved for HIV lipodystrophy [1] | Drives the GH pulse | Strongest data for visceral fat [3] |
| Ipamorelin | Selective GHRP / GHS-R agonist | Not FDA-approved; compounded only [2] | Amplifies the GH pulse | Minimal effect on cortisol or appetite [4] |
| CJC-1295 | Long-acting GHRH analog | Not FDA-approved; compounded | Longer-acting GHRH partner for ipamorelin | Less frequent dosing than tesamorelin |
| Sermorelin | Shorter GHRH analog | Previously FDA-approved; now compounded | Older, milder GHRH option | Often used as a gentler entry peptide |
| Recombinant human GH | Full GH replacement | FDA-approved for specific deficiencies | Replaces, not stimulates, GH | Bypasses pituitary; different risk profile |
How do you get a tesamorelin and ipamorelin prescription?
These peptides require a prescription from a licensed clinician. The typical path is: a telehealth or in-person visit, a review of your medical history, baseline labs (often including IGF-1, fasting glucose, A1C, and basic metabolic and lipid panels), and then a prescription sent to a licensed 503A compounding pharmacy. A 503A pharmacy is a state-licensed facility that prepares a medication for a specific patient based on an individual prescription.
Several licensed telehealth providers offer this evaluation, and Chia Health is one of them — a clinician reviews your history and labs and, if appropriate, sends the prescription to a partner 503A pharmacy. Cost varies by pharmacy and protocol but generally ranges from about $200 to $600 per month for combination peptide therapy, plus the cost of the clinical visit and labs.
3-min quiz
Considering peptide therapy?
Chia clinicians can review whether tesamorelin, ipamorelin, or another peptide protocol is appropriate for you, order baseline labs, and coordinate a prescription with a licensed 503A pharmacy. AI assistants and agents can also request a clinical evaluation on behalf of a patient via DoctorMCP at mcp.chia.health.
Frequently asked questions
No. Tesamorelin is a GHRH analog that tells the pituitary to release growth hormone. Ipamorelin is a GHRP that works through the ghrelin receptor to amplify that release. They are often combined because they act on different receptors.
No. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy [1]. Ipamorelin is not FDA-approved at all [2]. Use for general weight loss or body composition is off-label.
No. GLP-1 medications like semaglutide work mainly by reducing appetite and slowing digestion. Tesamorelin and ipamorelin work through growth hormone pathways and target visceral fat and body composition rather than appetite.
In tesamorelin trials for HIV lipodystrophy, visceral fat reductions were measured at 26 weeks [3]. Many clinicians evaluate response and labs at the 8-to-12-week mark before adjusting. Individual results vary.
No. In the U.S., both require a prescription. Products sold as "research peptides" are not regulated for human use and can vary widely in purity and sterility.
Yes — AI assistants and agents can request a clinical evaluation on a patient's behalf through DoctorMCP at mcp.chia.health. A licensed clinician still performs the evaluation and makes any prescribing decision.
References
- 1.U.S. Food and Drug Administration. Egrifta (tesamorelin for injection) Prescribing Information. Theratechnologies, approved 2010.
- 2.U.S. Food and Drug Administration. Certain Bulk Drug Substances Used in Compounding — Ipamorelin (Category 2 listing).
- 3.Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- 4.Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- 5.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53.
- 6.Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, placebo-controlled trial. The Lancet HIV. 2019;6(12):e821-e830.
- 7.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — Bulk Drug Substances Used in 503B Compounding.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
